4.1 Review

To Live or to Die: Prosurvival Activity of PPAR gamma in Cancers

Journal

PPAR RESEARCH
Volume 2008, Issue -, Pages -

Publisher

HINDAWI LTD
DOI: 10.1155/2008/209629

Keywords

-

Funding

  1. NHLBI NIH HHS [K08 HL068850] Funding Source: Medline

Ask authors/readers for more resources

The role of PPAR gamma in tumorigenesis is controversial. In this article, we review and analyze literature from the past decade that highlights the potential proneoplastic activity of PPAR gamma. We discuss the following five aspects of the nuclear hormone receptor and its agonists: (1) relative expression of PPAR gamma in human tumor versus normal tissues; (2) receptor-dependent proneoplastic effects; (3) impact of PPAR gamma and its agonists on tumors in animal models; (4) clinical trials of thiazolidinediones (TZDs) in human malignancies; (5) TZDs as chemopreventive agents in epidemiology studies. The focus is placed on the most relevant in vivo animal models and human data. In vitro cell line studies are included only when the effects are shown to be dependent on the PPAR gamma receptor. Copyright (C) 2008 Y. Lynn Wang and Q. Miao.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

System for Informatics in the Molecular Pathology Laboratory An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management

Wenjun Kang, Sabah Kadri, Rutika Puranik, Michelle N. Wurst, Sushant A. Patil, Ibro Mujacic, Sonia Benhamed, Nifang Niu, Chao Jie Zhen, Bekim Ameti, Bradley C. Long, Filipo Galbo, David Montes, Crystal Iracheta, Venessa L. Gamboa, Daisy Lopez, Michael Yourshaw, Carolyn A. Lawrence, Dara L. Aisner, Carrie Fitzpatrick, Megan E. McNerney, Y. Lynn Wang, Jorge Andrade, Samuel L. Volchenboum, Larissa Furtado, Lauren L. Ritterhouse, Jeremy P. Segal

JOURNAL OF MOLECULAR DIAGNOSTICS (2018)

Letter Pathology

MYD88 Mutations and Sensitivity to Ibrutinib Therapy

Y. Lynn Wang

JOURNAL OF MOLECULAR DIAGNOSTICS (2018)

Article Oncology

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Greg P. Coffey, Jiajia Feng, Andreas Betz, Anjali Pandey, Matt Birrell, Janet M. Leeds, Kenneth Der, Sabah Kadri, Pin Lu, Jeremy Segal, Y. Lynn Wang, Glenn Michelson, John T. Curnutte, Pamela B. Conley

CLINICAL CANCER RESEARCH (2019)

Article Oncology

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells

Seung-Cheol Lee, Alexander A. Shestov, Lili Guo, Qian Zhang, Jeffrey C. Roman, Xiaobin Liu, Hong Y. Wang, Stephen Pickup, Kavindra Nath, Pin Lu, Samuel Hofbauer, Clementina Mesaros, Y. Lynn Wang, David S. Nelson, Stephen J. Schuster, Ian A. Blair, Jerry D. Glickson, Mariusz A. Wasik

MOLECULAR CANCER RESEARCH (2019)

Review Pathology

Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia

Jimmy Lee, Y. Lynn Wang

JOURNAL OF MOLECULAR DIAGNOSTICS (2020)

Article Hematology

Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2

Wenjun Wu, Weige Wang, Carrie A. Franzen, Hui Guo, Jimmy Lee, Yan Li, Madina Sukhanova, Dong Sheng, Girish Venkataraman, Mei Ming, Pin Lu, Anhui Gao, Chunmei Xia, Jia Li, Liang Leo Zhang, Vivian Changying Jiang, Michael L. Wang, Jorge Andrade, Xiaoyan Zhou, Y. Lynn Wang

Summary: Inhibition of B-cell receptor signaling by ibrutinib affects cell adhesion in mantle cell lymphoma, with RAC2 playing a crucial role. This study highlights the importance of RAC2 and cell adhesion in MCL pathogenesis and drug development, demonstrating a novel link between BCR signaling and cell adhesion.

BLOOD ADVANCES (2021)

Article Oncology

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

Pin Lu, Shengchun Wang, Carrie A. Franzen, Girish Venkataraman, Rebecca McClure, Lei Li, Wenjun Wu, Nifang Niu, Madina Sukhanova, Jianming Pei, Donald A. Baldwin, Reza Nejati, Mariusz A. Wasik, Nadia Khan, Yifan Tu, Juehua Gao, Yihua Chen, Shuo Ma, Richard A. Larson, Y. Lynn Wang

Summary: Ibrutinib and venetoclax are effective as monotherapy for CLL, with better results when used in combination. They target different subpopulations within CLL and effectively reduce both subpopulations. Using a proliferation model may help identify novel drug combinations for eradicating residual disease.

BLOOD CANCER JOURNAL (2021)

Meeting Abstract Hematology

SHP1 Loss Augments DLBCL Cellular Response to Ibrutinib: A Candidate Predictive Biomarker

Y. Lynn Wang, Ji Ma, Vinay Mallikarjuna, Pin Lu, Shengchun Wang, Sahar Poureghbali, Mariusz A. Wasik, Reza Nejati, Wenjun Wu

BLOOD (2021)

Review Hematology

Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

Shazia Nakhoda, Aldana Vistarop, Y. Lynn Wang

Summary: Bruton tyrosine kinase inhibitors (BTKi) have had a significant impact on the treatment of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma. However, resistance to BTKi remains a challenge, and this review article provides an update on the key clinical data, mechanisms of resistance, and ongoing clinical investigations in CLL, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Biochemistry & Molecular Biology

SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker

Wenjun Wu, Pin Lu, Priyal Patel, Ji Ma, Kathy Qi Cai, Vinay S. Mallikarjuna, Sahar Poureghbali, Shazia R. Nakhoda, Reza Nejati, Y. Lynn Wang

Summary: Loss of SHP1 can serve as an alternative biomarker to identify patients who potentially benefit from ibrutinib treatment, and reducing SHP1 pharmacologically may represent a new strategy to augment tumor response to BCR-directed therapies.

ONCOGENE (2023)

Correction Hematology

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma (vol 2, pg 2039, 2018)

Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Shengjian Huang, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang

BLOOD ADVANCES (2018)

Article Hematology

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang

BLOOD ADVANCES (2018)

Meeting Abstract Pathology

TP53 Aberrations Predict for Worse Outcome in Diffuse Large B-cell Lymphoma - Richter transformation, A Single Institution Series of 76 Cases

Shiraz Fidai, Madina Sukhanova, Y. Lynn Wang, Sonali Smith, Wendy Stock, Elizabeth Hyjek, Girish Venkataraman

MODERN PATHOLOGY (2018)

Meeting Abstract Medicine, Research & Experimental

TP53 Aberrations Predict for Worse Outcome in Diffuse Large B-cell Lymphoma - Richter transformation, A Single Institution Series of 76 Cases

Shiraz Fidai, Madina Sukhanova, Y. Lynn Wang, Sonali Smith, Wendy Stock, Elizabeth Hyjek, Girish Venkataraman

LABORATORY INVESTIGATION (2018)

Article Oncology

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I kappa B

Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, Y. Lynn Wang

MOLECULAR CANCER THERAPEUTICS (2018)

No Data Available